GSK plans to close its vaccine manufacturing operation in Dresden, Germany, as declining demand for traditional egg-based influenza vaccines leaves the pharmaceutical group with more production capacity than it expects to require.
The company has reviewed the future of its flu vaccine manufacturing sites in Dresden and Ste-Foy, Canada, and intends to consolidate production at the Canadian operation. GSK expects the Dresden plant to close in summer 2027 if the proposal proceeds.
German chemical and energy union IGBCE says 641 jobs are at risk. Employees were informed of the plan on 10 September, and both the union and the plant’s works council have opposed the closure.
The Dresden operation produces traditional egg-based seasonal influenza vaccines and has also been associated with hepatitis vaccine production. Flu vaccine manufacture remains an established part of the pharmaceutical supply chain, but changes in demand and platform technology are altering the amount and type of capacity manufacturers expect to need over the next decade.
GSK’s stated rationale centres on utilisation. Demand for conventional egg-based products has declined sufficiently for the company to conclude that its two-site manufacturing footprint provides more capacity than anticipated future volumes justify. Ste-Foy is expected to meet the group’s requirements after consolidation.
The calculation is particularly important in vaccine manufacturing because excess capacity is expensive to keep available. Production facilities require specialist equipment, utilities, environmental controls, qualified personnel, validated processes, analytical laboratories, maintenance, and continuing regulatory oversight whether utilisation is high or low.
Reducing the number of manufacturing sites can therefore improve asset utilisation and remove duplicated fixed costs, although it also concentrates production geographically. Vaccine supply chains have spent the years since the Covid-19 pandemic balancing those competing requirements: resilience favours redundancy, while commercial efficiency generally rewards well-used capacity.
The proposed closure also arrives as GSK advances an mRNA seasonal influenza vaccine candidate into late-stage development. Messenger RNA products use a fundamentally different production platform from conventional egg-based vaccines, with different raw materials, equipment, process controls, analytical methods, and supply requirements.
The development does not mean Dresden is simply being replaced by an mRNA factory elsewhere. GSK’s immediate explanation is falling demand for traditional products and available capacity at Ste-Foy, while the eventual commercial role of the newer vaccine still depends on successful clinical development, regulatory approval, market demand, and manufacturing scale-up.
The workforce consequences are more immediate. Vaccine plants employ process engineers, microbiologists, maintenance specialists, quality-control and quality-assurance teams, validation personnel, utility engineers, warehouse staff, cold-chain specialists, and other functions required to operate within tightly controlled pharmaceutical manufacturing systems.
Once those teams disperse, recreating the same capability is considerably slower than reopening an ordinary industrial building. Pharmaceutical manufacturing knowledge sits partly in documented procedures and partly in employees’ experience of particular processes, equipment, deviations, quality systems, and regulatory inspections.
IGBCE has placed the Dresden proposal within a wider deterioration in industrial employment across Saxony, estimating that around 4,250 jobs are affected by recent restructuring and loss plans in industries it represents. That is a union figure covering several sectors rather than pharmaceutical manufacturing alone, but it explains why the GSK announcement has attracted concern beyond the plant.
Germany has also spent recent years debating the resilience of European pharmaceutical production and dependence on overseas supply chains. The Dresden decision illustrates the awkward boundary between that policy ambition and individual manufacturing economics: governments may want domestic capacity retained, while companies still have to decide whether enough product exists to keep each validated site commercially viable.
GSK continues to operate other activities in Germany, so the proposal is not an exit from the country’s life-sciences sector. The Dresden plant is nevertheless a specialist production asset with a workforce built around regulated vaccine manufacturing, and closure would remove that capability from the region rather than merely transfer office functions.
The proposal now moves through the employee consultation and closure process, with the union seeking alternatives that would preserve production and employment. Unless that process produces a different industrial plan, manufacturing is expected to be consolidated into Ste-Foy before Dresden closes in summer 2027.
Over the same period, GSK’s influenza portfolio will continue shifting as newer vaccine technologies progress through development. The two timelines are not identical, but together they show how changes in product demand and production technology can leave long-established pharmaceutical assets facing decisions years before the replacement technologies themselves become routine.
